Key Takeaways
- Glenn Brammer, MD, at Augusta Health now offers the Abbott Volt™ Pulsed Field Ablation (PFA) System for treating atrial fibrillation (AFib).
- PFA uses high‑energy electrical pulses rather than heat or cold, reducing damage to surrounding heart tissue compared with conventional thermal ablation.
- AFib affects roughly 12 million Americans over 65 and is projected to double in the next two decades; patients with AFib are five times more likely to suffer a stroke.
- Augusta Health’s cardiovascular program continues to expand, highlighted by its 250th Pulse Select PFA procedure, over 300 CathWorks cases, initial CathPCI accreditation, and 30‑year IAC vascular accreditation.
- The adoption of Abbott’s state‑of‑the‑art PFA system reflects a broader commitment to providing innovative, minimally invasive arrhythmia treatments locally.
Introduction of Abbott Volt™ PFA at Augusta Health
Glenn Brammer, MD, a cardiac electrophysiologist and cardiologist with Augusta Health, has begun offering the Abbott Volt™ Pulsed Field Ablation System to patients suffering from atrial fibrillation (AFib). This marks a significant step forward for the health system’s electrophysiology service, positioning Augusta Health among the early adopters of the latest pulsed field ablation technology in the region. Dr. Brammer’s expertise in cardiac rhythm disorders ensures that patients receive precise, state‑of‑the‑art care tailored to their individual needs. The introduction of this system underscores Augusta Health’s dedication to integrating cutting‑edge medical devices that improve outcomes and enhance the patient experience.
Burden of Atrial Fibrillation and the Need for Advanced Therapies
Atrial fibrillation and related cardiac arrhythmias impose a substantial burden on millions of individuals both in the United States and worldwide. Beyond the day‑to‑day discomfort of shortness of breath, dizziness, and chest pain, untreated AFib markedly elevates the risk of stroke and heart attack. Christopher Piorkowski, M.D., chief medical officer of Abbott’s electrophysiology business, emphasized that the growing adoption of pulsed field ablation technology holds promise for alleviating this burden. He noted that Abbott’s Volt™ system overcomes limitations seen in earlier‑generation PFA platforms, offering a safer, more effective alternative for patients whose arrhythmias persist despite medication.
Epidemiology and Clinical Rationale for Ablation
Current estimates indicate that approximately 12 million people aged 65 and older in the United States live with AFib, a figure expected to double within the next 20 years. Individuals with AFib face a five‑fold increase in stroke risk, and the condition has remained a leading or contributing cause of death in the U.S. for over two decades. When pharmacologic therapy and lifestyle modifications fail to control the arrhythmia, many patients turn to cardiac ablation—a minimally invasive procedure designed to isolate and eliminate the aberrant electrical pathways responsible for irregular heart rhythms. The availability of advanced ablation tools like the Abbott Volt™ system therefore addresses a critical unmet need in the management of this prevalent condition.
Physician Perspective on Patient Trust and Care Commitment
Dr. Brammer articulated the profound responsibility inherent in each ablation procedure, stating, “Every ablation represents a patient trusting our team with their heart health.” He viewed the adoption of the Abbott Volt™ system not merely as a technological upgrade but as a testament to the entire care team’s dedication to offering advanced treatment options while maintaining a high standard of patient experience locally. This sentiment reflects Augusta Health’s broader philosophy of combining clinical excellence with compassionate, community‑focused care, ensuring that patients feel supported throughout their treatment journey.
Mechanistic Advantages of Pulsed Field Ablation Over Thermal Techniques
Unlike traditional thermal ablation—which relies on extreme heat (radiofrequency) or cold (cryoenergy) to create lesions in cardiac tissue—pulsed field ablation delivers short, high‑energy electrical pulses that irreversibly permeabilize cell membranes in the targeted area. This non‑thermal approach selectively affects cardiac muscle while sparing adjacent structures such as the esophagus, pulmonary veins, and phrenic nerve, thereby lowering the risk of procedural complications like esophageal injury or pulmonary vein stenosis. The precision and safety profile of PFA make it especially attractive for patients with complex anatomies or those who have previously undergone unsuccessful ablation attempts.
Leadership Enthusiasm for the New Technology at Augusta Health
Kris Doan, MBA, FACHE, President of Augusta Medical Group, expressed enthusiasm about the health system’s ability to offer the Abbott Volt™ PFA system. “A healthy heart is key to a healthy life. At Augusta Health, we are excited to offer this new ablation system. Our goal is to help patients manage difficult arrhythmias so they can return to the activities they love,” Doan remarked. This optimism is rooted in the belief that providing access to innovative, less invasive therapies will improve quality of life, reduce hospital readmissions, and empower patients to resume normal daily functions and enjoy everyday activities without the limitations imposed by uncontrolled arrhythmias.
Program Milestones Demonstrating Ongoing Advancement
The launch of the Abbott Volt™ system builds upon a year of notable progress within Augusta Health’s cardiovascular program. Highlights include performing the 250th Pulse Select pulsed field ablation procedure, completing more than 300 CathWorks procedures (which utilize AI‑guided coronary angiography), earning initial CathPCI accreditation from the American College of Cardiology, and receiving recognition for its 30‑year IAC Vascular Accreditation. Collectively, these achievements illustrate Augusta Health’s commitment to maintaining high standards of care, embracing technological innovation, and continuously expanding its capabilities to serve the community effectively.
Conclusion: Impact on Patient Care and Future Directions
The introduction of Abbott’s Volt™ Pulsed Field Ablation System at Augusta Health represents a meaningful advancement in the treatment of atrial fibrillation. By leveraging a non‑thermal, tissue‑selective energy source, the technology offers a safer alternative to conventional ablation methods, potentially reducing complications and improving long‑term success rates. Coupled with the health system’s expanding electrophysiology volume, procedural accolades, and patient‑centered ethos, this development positions Augusta Health to better address the rising prevalence of AFib and its associated risks. As pulsed field ablation continues to gain traction globally, local patients stand to benefit from cutting‑edge care that enables them to regain heart health and return to the lifestyles they value.